Negev Capital partner Ken Belotsky speaks to Thomas Warner from Proactive about the opportunities presented by the psychedelic startup scene. Belotsky describes the pharmaceutical market as "pretty conservative" overall, but says he believes that "soon we will see examples of M&A activity from big pharma into psychedelics, and as soon as it happens we will see a completely different [level of] interest from funds in the psychedelic space."
The interview concludes with Belotsky discussing Negev Capital's sponsorship of the upcoming PSYCH symposium in London.